idelalisib + venetoclax + rituximab

This combination regimen, often referred to as RIVe, consists of the PI3K delta inhibitor idelalisib, the BCL-2 inhibitor venetoclax, and the anti-CD20 monoclonal antibody rituximab. It is being evaluated in the Phase 1 RIVe-CLL/SLL trial (NCT03639324) sponsored by Virginia Commonwealth University for the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). The regimen utilizes a multi-targeted approach: idelalisib disrupts B-cell receptor signaling and survival pathways, venetoclax restores apoptotic mechanisms by inhibiting the anti-apoptotic protein BCL-2, and rituximab targets CD20-positive B-cells for immune-mediated destruction. The specific 'dose combination 1-4' refers to a regimen of 150 mg BID idelalisib and 200 mg QD venetoclax administered alongside rituximab.

Brand names

ZydeligVenclextaRituxanMabThera

Other names

dose combination 1-4-Virginia Commonwealth University-chronic lymphocytic leukemia-small lymphocytic lymphomaidelalisib + venetoclax + rituximab combination